NataliyaVUbohaMDPhD

Oncology • Madison, WI

Hematologic Oncology

Physician

Join to view full profile

Dr. Uboha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Uboha's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-266-6020

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Yale-New Haven Medical CenterResidency, Internal Medicine, 2007 - 2010
Yale School of MedicineClass of 2007

Certifications & Licensure

WI State Medical License 2015 - 2025
CT State Medical License 2010 - 2015
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs Start of enrollment: 2017 Aug 22
Terminated
Phase 1
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer Start of enrollment: 2018 May 29
Active, not recruiting
Phase 1, Phase 2
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 Start of enrollment: 2019 Aug 26
Terminated
Phase 2
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma Start of enrollment: 2020 Jul 13
Recruiting
Phase 2
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body Start of enrollment: 2020 May 26
Recruiting
Phase 3
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Start of enrollment: 2020 Mar 01
Active, not recruiting
Phase 3
Roles: Contact
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Start of enrollment: 2024 Mar 08
Recruiting
Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer.
Nataliya V Uboha, Mustafa M Basree, Jens C Eickhoff, Dustin A Deming, Kristina Matkowskyj
Journal of Surgical Oncology. 2025-01-05
A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Bi...
Marie S Dreyer, Mary Mulcahy, Masha Kocherginsky, Yolande Chen, Howard S Hochster
The Oncologist. 2024-12-06
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Petros Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal
Clinical Cancer Research. 2024-10-15

Lectures

Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Resea...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020

Press Mentions

Clinical Scenarios and Approaches to Treating Locally Advanced Esophageal AdenocarcinomaAugust 28th, 2024
Bispecific Antibodies in Gastric Cancer: Big Questions but Bigger Potential?August 26th, 2024
Chemotherapy-Immunotherapy Combination Shows Efficacy in Esophagogastric Cancer SubsetJuly 12th, 2022
Join now to see all